MyFinsight
Home
Blog
About
Contact
Restricted cash
$8,000,000
Prepaid expenses
$2,625,169
Short term
investments
$1,500,000
Cash & cash
equivalents
$979,534
Other current assets
$48,500
Digital assets, at fair
value
$127,815,173
Total current assets
$13,153,203
Operating lease rou asset,
net
$171,779
Property and equipment,
net
$56,592
Long-term portion of
prepaid expenses
$22,410
Total assets
$141,219,157
Total liabilities and
shareholders equity
$141,219,157
Total shareholders
equity
$126,515,459
Total liabilities
$14,703,698
Accumulated deficit
-$45,452,913
Additional paid-in capital
$163,654,524
Total current
liabilities
$14,584,883
Long-term portion of
operating lease liability
$118,815
Common shares to be
issued
$8,113,318
Common stock, par value
0.01, 100,000,000...
$125,760
Preferred stock, par value
0.01, 10,000,000...
$74,770
Convertible notes, net
$7,942,281
Accounts payable and
accrued expenses
$2,978,190
Derivative liability
$1,568,634
Notes payable, net
$920,000
Accrued offering costs
$575,000
Notes payable -
related party
$500,100
Operating lease liability
$52,339
Accrued interest -
related party
$36,339
Advance payable to
related party
$12,000
Back
Back
Balance Sheet
Apimeds Pharmaceuticals US, Inc. (APUS)
Apimeds Pharmaceuticals US, Inc. (APUS)
source: myfinsight.com